Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of lonoctocog alfa in Chinese previously treated patients with severe hemophilia A
2023-001026-34Phase 3
- Sponsor
- CSL Limited
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lonoctocog alfa in hemophilia A, sponsored by CSL Limited. Primary endpoint: Incremental Recovery (IR) of rVIII-SingleChain.
02
Drugs
lonoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2023-001026-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-001026-34.